| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HELICOBACTER PYLORI |
1 Otto-von-Guericke University of Magdeburg, Magdeburg, Germany
2 INSERM U853, Bordeaux, France
3 Adelaide and Meath Hospital, Trinity College, Dublin, Ireland
4 University of Bologna, Bologna, Italy
5 Aberdeen University, Aberdeen, UK
6 VA Medical Center Houston, Texas, USA
7 McMaster University, Hamilton, Ontario, Canada
8 Henry-Dunant Hospital, Athens, Greece
9 University of Wisconsin Medical School, Milwaukee, USA
10 Erasmus MC University Medical Center, Rotterdam, Netherlands
Correspondence to:
Correspondence to:
Professor P Malfertheiner
Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät, Zentrum für Innere Medizin, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Leipziger Straße 44, D-39120 Magdeburg, Germany; peter.malfertheiner{at}medizin.uni-magdeburg.de
Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000.
Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer.
Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility.
Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
Abbreviations: BabA2, blood group antigen binding adhesin 2; CagA, cytotoxin associated gene A; EHSG, European Helicobacter Study Group; GORD, gastro-oesophageal reflux disease; IDA, iron deficiency anaemia; ITP, idiopathic thrombocytopenic purpura; MALT, mucosa associated lymphoid tissue; NSAIDs, non-steroidal anti-inflammatory drugs; OipA, outer inflammatory protein A; PPIs, proton pump inhibitors; RCT, randomised controlled trial; SabA, sialic acid binding adhesion; UBT, 13C-urea breath test; VacA, vacuolating associated gene A
Keywords: H pylori; diseases; diagnosis; treatment; prevention
Relevant Article
Gut 2007 56: 741.
This article has been cited by other articles:
|
|
 |
|
  Y.-C. Lee, J.-M. Liou, C.-Y. Wu, and J.-T. Lin Review: Eradication of Helicobacter pylori to prevent gastroduodenal diseases: Hitting more than one bird with the same stone Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 111 - 120. [Abstract] [PDF]
|
|
|
|
 |
|
 A De Schryver, K Cornelis, M Van Winckel, G Moens, G Devlies, D Derthoo, and M van Sprundel The occupational risk of Helicobacter pylori infection among workers in institutions for people with intellectual disability Occup. Environ. Med., September 1, 2008; 65(9): 587 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Mahadeva, Y-C Chia, A Vinothini, M Mohazmi, and K-L Goh Cost-effectiveness of and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia Gut, September 1, 2008; 57(9): 1214 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Lundell, S Attwood, C Ell, R Fiocca, J-P Galmiche, J Hatlebakk, T Lind, O Junghard, and on behalf of the LOTUS trial collaborators Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial Gut, September 1, 2008; 57(9): 1207 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kiltz, J. Zochling, W. E. Schmidt, and J. Braun Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology, September 1, 2008; 47(9): 1342 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Burucoa, M. Garnier, C. Silvain, and J.-L. Fauchere Quadruplex Real-Time PCR Assay Using Allele-Specific Scorpion Primers for Detection of Mutations Conferring Clarithromycin Resistance to Helicobacter pylori J. Clin. Microbiol., July 1, 2008; 46(7): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Jafri, C. A. Hornung, and C. W. Howden Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment Ann Intern Med, June 17, 2008; 148(12): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Krausse, G. Muller, and M. Doniec Evaluation of a Rapid New Stool Antigen Test for Diagnosis of Helicobacter pylori Infection in Adult Patients J. Clin. Microbiol., June 1, 2008; 46(6): 2062 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-W. Lee, B. Rickman, A. B. Rogers, Z. Ge, T. C. Wang, and J. G. Fox Helicobacter pylori Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice Cancer Res., May 1, 2008; 68(9): 3540 - 3548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fuccio, R. M. Zagari, and F. Bazzoli Could Increasing the Duration of Triple Therapy Be a Clinically Useful Strategy? Ann Intern Med, April 15, 2008; 148(8): 624 - 625. [Full Text] [PDF]
|
|
|
|
 |
|
 B. C Delaney, M. Qume, P. Moayyedi, R. F A Logan, A. C Ford, C. Elliott, C. McNulty, S. Wilson, and F D R. Hobbs Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial) BMJ, March 22, 2008; 336(7645): 651 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fuccio, M. E. Minardi, R. M. Zagari, D. Grilli, N. Magrini, and F. Bazzoli Meta-analysis: Duration of First-Line Proton-Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication Ann Intern Med, October 16, 2007; 147(8): 553 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Peyrin-Biroulet, J.-L. Gueant, A M C Rocha, G A Rocha, M C A Marino, and D M M Queiroz Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients? * Author's reply Gut, October 1, 2007; 56(10): 1480 - 1481. [Full Text] [PDF]
|
|
|
|
|
|
A. Zullo, V. De Francesco, C. Hassan, S. Morini, and D. Vaira The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis Gut, October 1, 2007; 56(10): 1353 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vaira, A. Zullo, and N. Vakil Ethical Considerations of Comparing Sequential and Traditional Anti Helicobacter pylori Therapy Ann Intern Med, September 18, 2007; 147(6): 435 - 436. [Full Text] [PDF]
|
|
|
|
|
|
D. Y Graham, Y. Yamaoka, R. M. Zagari, and F. Bazzoli One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm * Authors' response Gut, July 1, 2007; 56(7): 1021 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Megraud and P. Lehours Helicobacter pylori Detection and Antimicrobial Susceptibility Testing Clin. Microbiol. Rev., April 1, 2007; 20(2): 280 - 322. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
